Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Maria Melanson"'
Autor:
Denise Bury, Nadia Daizadeh, David Cella, David Margolin, Jennifer D Guo, Rafael Arroyo, Maria Melanson
Publikováno v:
Multiple Sclerosis (Houndmills, Basingstoke, England)
Background: In CARE-MS II (Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis; NCT00548405), alemtuzumab (12 mg/day; baseline: 5 days; 12 months later: 3 days) significantly improved health-related quality of life (HRQL) outcomes ve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8eb52268f02cef6ff172e7eaf00cfcc
https://doi.org/10.1177/1352458519849796
https://doi.org/10.1177/1352458519849796
Publikováno v:
Journal of Cardiac Failure. 25:S111-S112
Hereditary transthyretin-mediated (hATTR) amyloidosis is an inherited, progressively debilitating, fatal disease caused by a mutation in the transthyretin (TTR) gene. hATTR amyloidosis results in abnormal amyloid accumulation in multiple sites causin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fac5689a0822f120949050d932d75825
https://doi.org/10.1016/j.cardfail.2019.07.318
https://doi.org/10.1016/j.cardfail.2019.07.318
Autor:
Tatiana Sidorenko, Aaron Boster, Ouali Berkani, Maria Melanson, Oscar Fernández, Markus S. Mueller, Tomas Olsson, Mark S. Freedman, Carlo Pozzilli, Doris Bach, Ernst Wilhelm Radue
Publikováno v:
Journal of Neurology, Neurosurgery & Psychiatry. 85:1198-1208
This double-blind, placebo-controlled, dose-finding phase IIb study evaluated the efficacy and safety of ponesimod, an oral selective S1P1 receptor modulator, for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS).464 patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9dbda09d4075fddf184e4c41285ed45
https://doi.org/10.1136/jnnp-2013-307282
https://doi.org/10.1136/jnnp-2013-307282
Autor:
Andrew Gomori, Meghann Klowak, Michael Prout, Farid Esfahani, Michael Namaka, Romeo Hizon, Amy Grossberndt, Christine Leong, Michael R. Mulvey, Loressa Klassen, Maria Melanson, Malcolm Doupe, Aneri Gupta, Emma E. Frost
Publikováno v:
Multiple Sclerosis Journal. 17:397-403
Background: Staphylococcus aureus may produce superantigens that can non-specifically activate CD4+ cells to potentially target the myelin basic protein. Objective: This study examined the association between individuals with multiple sclerosis (MS)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c429a45325ce5451361150d488150e4
https://doi.org/10.1177/1352458510391343
https://doi.org/10.1177/1352458510391343
Autor:
Michael Prout, Michael Namaka, Andrew Gomori, Meghann Klowak, Maria Melanson, Emma E. Frost, Colin R. Gramlich, Lisa Wong, Malcom Doupe, Amy Grossberndt, Christine Leong, Farid Esfahani, Josee-Anne Le Dorze
Publikováno v:
International Journal of Neuroscience. 120:631-640
Fatigue and cognitive deficits are common symptoms affecting patients with multiple sclerosis.The effects of interferon beta on fatigue and cognitive deficits were assessed in 50 patients with relapsing multiple sclerosis (recruited at a single cente
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b282f1b3cfc0bc1fa3c5757532930b44
https://doi.org/10.3109/00207454.2010.511732
https://doi.org/10.3109/00207454.2010.511732
Autor:
Carlo Pozzilli, Alexey Boyko, Maria Melanson, Hans-Peter Hartung, Topaz investigators, Patrick Vermersch, Bart Van Wijmeersch, Pamela A. McCombe, Nadia Daizadeh, Claudio E Rodriguez, Eva Havrdova, Xavier Montalban, Krzysztof Selmaj, Jérôme DeSeze, Jihad Inshasi
Publikováno v:
Journal of Neurology, Neurosurgery & Psychiatry. 89:A18.2-A19
IntroductionIn CARE-MS I (NCT00530348), alemtuzumab 12 mg/day (baseline: 5 days; 12 months later: 3 days) improved clinical/MRI outcomes versus SC IFNB-1a over 2 years (y) in treatment-naive relapsing-remitting MS (RRMS) patients. Efficacy was durabl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5a7abc2cdc20a0050835b5b1fb2adcb2
https://doi.org/10.1136/jnnp-2018-anzan.43
https://doi.org/10.1136/jnnp-2018-anzan.43
Autor:
Marcus Vasconcelos, Meghann Klowak, Andrea Doupe, Arla Crook, Maria Melanson, Yuewen Gong, Kulwinder Kler, Mike Namaka, Alicja Wojewnik-Smith
Publikováno v:
Neurological Research. 30:710-719
The purpose of this article is to provide a comprehensive overview of the most frequently encountered non-conventional approaches trialed for use in multiple sclerosis (MS). The efficacy and safety of non-conventional approaches ranging from bee veno
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8ef1de2f32e6a350a83baa5e19ef58a
https://doi.org/10.1179/174313208x325038
https://doi.org/10.1179/174313208x325038
Publikováno v:
Canadian Pharmacists Journal / Revue des Pharmaciens du Canada. 138:1-13
Although a rare disease, multiple sclerosis (MS) has a high prevalence rate in Canada and affects many Canadians and their families. An autoimmune disease of the central nervous system, it results in the destruction of the myelin sheath that surround
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e7fbba4f0cef5c85e12afbac7cc7d74f
https://doi.org/10.1177/171516350513800601
https://doi.org/10.1177/171516350513800601
Autor:
Christine Leong, Meghann Klowak, David Eisenstat, Yuewen Gong, Pinhui Miao, Hong Shen, Kim Madec, Xiaochen Gu, Michael Namaka, Maria Melanson
Publikováno v:
Neurological research. 30(6)
Neuropathic pain is a chronic pain syndrome associated with drug, injury or disease-induced damage or destruction of sensory afferent fibers of the dorsal root ganglia (DRG). Although the exact underlying pathologic mechanisms are not known, pro-infl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e42421116724b280b1e0061d71ac5dd4
https://pubmed.ncbi.nlm.nih.gov/18489817
https://pubmed.ncbi.nlm.nih.gov/18489817
Autor:
Yuewen Gong, Aneri Gupta, Meghann Klowak, Marcus Vasconcelos, Maria Melanson, Mike Namaka, Merinda Pollitt-Smith, Dana Turcotte
Publikováno v:
Current medical research and opinion. 22(2)
Neutralizing antibodies (NAbs) develop in patients receiving interferon beta (IFN-beta) for multiple sclerosis (MS). Debate continues concerning the relevance of NAb development on treatment efficacy.To determine the incidence and clinical importance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b17945401c46767fb258ab0d4abe79eb
https://pubmed.ncbi.nlm.nih.gov/16466595
https://pubmed.ncbi.nlm.nih.gov/16466595